Clinical performance of 3 commercially available point-of-care antibody tests for Brucella canis in dogs.

FASTest® BRUCELLA canis POC assay performs well for B. canis screening but requires confirmatory testing.

This study evaluated the diagnostic performance of three commercially available point-of-care (POC) lateral flow assays for detecting Brucella canis antibodies in dogs, using the Canine Brucella Multiplex (CBM) assay as the reference standard. Fifty serum samples from client-owned dogs were tested: 10 culture-positive dogs and 40 healthy dogs undergoing export screening. The Anigen Rapid C.Brucella Ab assay demonstrated 90% positive percent agreement (PPA) and 100% negative percent agreement (NPA). The FASTest® BRUCELLA canis assay showed superior performance with 100% PPA and 92.5% NPA. The Canine Brucella LPS Antibody Rapid Test was unsuitable for clinical use with 0% PPA. Inter-reader agreement was excellent for all assays (κ = 0.81-1.00). Two of the three assays showed good correlation with the reference CBM assay and may serve as useful rule-out tests in clinically suspected cases. However, due to potential false negatives and false positives in low-prevalence settings, confirmatory testing is recommended for positive results.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.